Roger Paredes

Summary

Affiliation: Hospital Universitari Germans Trias i Pujol
Country: Spain

Publications

  1. pmc Limited cross-border infections in patients newly diagnosed with HIV in Europe
    Dineke Frentz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Retrovirology 10:36. 2013
  2. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
  3. pmc Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes
    Roger Paredes
    IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain
    J Infect Dis 207:S93-100. 2013
  4. doi request reprint Clinical management of HIV-1 resistance
    Roger Paredes
    Institut de Recerca de SIDA irsiCaixa and Fundació Lluita contra SIDA, Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Catalonia, Spain
    Antiviral Res 85:245-65. 2010
  5. ncbi request reprint Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    Lidia Ruiz
    Fundació IrsiCaixa and HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 21:169-78. 2007
  6. pmc Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects
    Francisco M Codoñer
    Institut de Recerca de la SIDA irsiCaixa HIVACAT, Badalona, Spain
    PLoS ONE 6:e19461. 2011
  7. ncbi request reprint Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain
    Clin Infect Dis 41:901-5. 2005
  8. ncbi request reprint Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients
    Anna Bonjoch
    Lluita contra la SIDA Found, AIDS Care Unit, Universitat Autonoma de Barcelona, Hospital Germans Trias i Pujol, Badalona
    AIDS Res Hum Retroviruses 22:321-9. 2006
  9. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Antivir Ther 9:889-93. 2004
  10. ncbi request reprint Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART
    Anna Bonjoch
    AIDS Care Unit, Lluita contra le SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 39:313-6. 2005

Collaborators

Detail Information

Publications35

  1. pmc Limited cross-border infections in patients newly diagnosed with HIV in Europe
    Dineke Frentz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Retrovirology 10:36. 2013
    ..In this study, phylogenetic associations among HIV of newly diagnosed patients were determined across Europe...
  2. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
    ..Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes...
  3. pmc Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes
    Roger Paredes
    IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain
    J Infect Dis 207:S93-100. 2013
    ....
  4. doi request reprint Clinical management of HIV-1 resistance
    Roger Paredes
    Institut de Recerca de SIDA irsiCaixa and Fundació Lluita contra SIDA, Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Catalonia, Spain
    Antiviral Res 85:245-65. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010...
  5. ncbi request reprint Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    Lidia Ruiz
    Fundació IrsiCaixa and HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 21:169-78. 2007
    ..We evaluated the safety of CD4 cell count and plasma HIV-1 RNA (pVL)-guided treatment interruptions (GTI) and determined predictors of duration of treatment interruption...
  6. pmc Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects
    Francisco M Codoñer
    Institut de Recerca de la SIDA irsiCaixa HIVACAT, Badalona, Spain
    PLoS ONE 6:e19461. 2011
    ..To explore the potential of deep HIV-1 sequencing for adding clinically relevant information relative to viral population sequencing in heavily pre-treated HIV-1-infected subjects...
  7. ncbi request reprint Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain
    Clin Infect Dis 41:901-5. 2005
    ..Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period...
  8. ncbi request reprint Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients
    Anna Bonjoch
    Lluita contra la SIDA Found, AIDS Care Unit, Universitat Autonoma de Barcelona, Hospital Germans Trias i Pujol, Badalona
    AIDS Res Hum Retroviruses 22:321-9. 2006
    ..34, 95% CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained...
  9. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Antivir Ther 9:889-93. 2004
    ..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term...
  10. ncbi request reprint Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART
    Anna Bonjoch
    AIDS Care Unit, Lluita contra le SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 39:313-6. 2005
    ..coformulated zidovudine/lamivudine plus nevirapine (group 2) in HIV-1-infected patients receiving successful first-line highly active antiretroviral therapy...
  11. doi request reprint Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial
    Anna Bonjoch
    HIV Unit and Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:1382-7. 2013
    ..To evaluate the safety and efficacy of switching the third drug of antiretroviral treatment to maraviroc in aviraemic subjects infected with R5 HIV...
  12. ncbi request reprint Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
    Carmina R Fumaz
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 29:244-53. 2002
    ....
  13. pmc HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization
    Christian Pou
    Institut de Recerca de la SIDA irsiCaixa HIVACAT, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Catalonia, Spain
    PLoS ONE 8:e67085. 2013
    ..The preferable tropism testing strategy in subjects with undetectable HIV-1 viremia, in whom plasma tropism testing is not feasible, remains uncertain...
  14. ncbi request reprint Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load
    Eugenia Negredo
    Lluita contra la SIDA and Irsicaixa Foundations Germans Trias i Pujol Hospital, Badalona, Spain
    AIDS 18:459-63. 2004
    ..We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression...
  15. ncbi request reprint New antiretroviral drugs and approaches to HIV treatment
    Roger Paredes
    IrsiCaixa Foundation and Retrovirology Laboratory, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 17:S85-96. 2003
  16. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  17. ncbi request reprint HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain
    Beatriz Mothe
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
    Curr HIV Res 7:597-600. 2009
    ..Based on our findings, we suggest some recommendations regarding the management of this growing population...
  18. ncbi request reprint Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:1383-9. 2002
    ..Treatment simplification approaches in which PI are replaced by nevirapine (NVP) have been shown to improve PI-related toxicity...
  19. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  20. pmc In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection
    Judith Dalmau
    AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e32714. 2012
    ....
  21. pmc Deep molecular characterization of HIV-1 dynamics under suppressive HAART
    Maria J Buzon
    Institut de Recerca de la SIDA, IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    PLoS Pathog 7:e1002314. 2011
    ....
  22. pmc Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
    Marc Noguera-Julian
    IrsiCaixa AIDS Research Institute HIVACAT, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet s n, Badalona 08916, Catalonia, Spain
    Virol J 10:350. 2013
    ..The goal of this study was to characterize viral resistance emergence and address viral population evolution during the first phase of viral decay after treatment containing initiation...
  23. ncbi request reprint Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression
    Judith Dalmau
    aAIDS Research Institute IrsiCaixa iInstitut d Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain bInstitute of Microbiology, University Hospital Center and University of Lausanne, Lausanne cUniversity Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland dUniversidad Complutense de Madrid, Madrid, Spain eMonogram Biosciences, South San Francisco, California, USA fCentre d Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya CEEISCAT, Badalona gBanc de Sang i Teixits, Barcelona hUniversitat de Vic UVic UCC, Vic iInstitució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain Judith Dalmau and Margalida Rotger contributed equally to this article Amalio Talenti, Javier Martinez Picado and Julia G Prado contributed equally to the work
    AIDS 28:1261-72. 2014
    ..Nevertheless, identification and characterization of the viral and host factors involved in rapid progression are crucial when attempting to uncover the correlates of rapid disease outcome...
  24. doi request reprint No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing
    Sandra Franco
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Clin Virol 58:726-9. 2013
    ..The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors...
  25. ncbi request reprint Reversal of HIV-1-associated osteoporosis with once-weekly alendronate
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS 19:343-5. 2005
    ..Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis...
  26. pmc RECall for automated genotypic tropism testing
    Christian Pou
    IrsiCaixa Institute for AIDS Research, Badalona, Catalonia, Spain
    J Clin Microbiol 51:2754-7. 2013
    ....
  27. ncbi request reprint The potential role of interleukin-2 in patients with HIV infection
    Roger Paredes
    Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    AIDS Rev 4:36-40. 2002
    ..The results of the phase III studies should provide an answer to the question of whether or not this is a strategy that will be of clinical benefit...
  28. pmc Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection
    Judith Dalmau
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Infect Dis 48:229-38. 2009
    ..However, clinically severe presentations during acute HIV type 1 (HIV-1) infection, including AIDS-defining symptoms, are unusual...
  29. doi request reprint Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:833-41. 2011
    ..It is uncertain whether a 4-week induction period of pegylated interferon and ribavirin increases early virological response (EVR) in HIV-HCV-coinfected patients...
  30. doi request reprint Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
    Francisco M Codoñer
    HIVACAT, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antiviral Res 88:281-6. 2010
    ....
  31. pmc CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control
    Beatriz Mothe
    IrsiCaixa AIDS Research Institute HIVACAT, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e29717. 2012
    ....
  32. doi request reprint HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32
    Ester Ballana
    IrsiCaixa and AIDS Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Immunobiology 218:543-7. 2013
    ..Importantly, the accumulation of protective factors does not warrant a complete protection to HIV infection and the subsequent life-long treatment...
  33. ncbi request reprint Disseminated cryptococcosis resembling milliary tuberculosis in an HIV-1-infected patient
    Virginia Pomar
    Infectious Diseases Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, St Antoni Maria Claret 167, Barcelona 08025, Catalonia, Spain
    Lancet Infect Dis 5:189. 2005
  34. ncbi request reprint Clinical approach to drug resistance interpretation: expert advice
    Bonaventura Clotet
    HIV Unit and Retrovirology Laboratory Irsicaixa Foundation, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain
    Curr Opin HIV AIDS 2:145-9. 2007
    ..It provides a continuous update to clinicians and can be made easily and broadly available through conference calls...
  35. ncbi request reprint Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression
    Eugenia Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Clin Infect Dis 34:504-10. 2002
    ..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective...